Quantum BioPharma's Unbuzzd Gains Credibility with Men's Fitness Review of Placebo-Controlled Trial

Quantum BioPharma's unbuzzd supplement, designed to support alcohol metabolism, has drawn praise from Men's Fitness after a placebo-controlled trial showed lower estimated blood alcohol concentration and reduced headache severity, lending credibility to the company's consumer health strategy.

Chicago Metrowire Staff
••Healthcare
Quantum BioPharma's Unbuzzd Gains Credibility with Men's Fitness Review of Placebo-Controlled Trial

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative, metabolic and alcohol misuse disorders, has invented unbuzzd, a supplement drink designed to support alcohol metabolism, and retains royalty and equity interests in the consumer brand. The company's shares trade under the ticker QNTM, and its pipeline spans several areas of unmet medical need. The Men's Fitness coverage arrives as the market for alcohol recovery products faces growing scrutiny over efficacy claims, and a placebo-controlled trial is a key differentiator in that landscape.

Earlier this month, Men's Fitness reviewed the unbuzzd clinical trial and described the early study findings as "promising." The magazine noted that "a small clinical trial found improvements in alcohol readings, alertness, and headache symptoms . . . [offering] early encouragement." Researchers reported lower estimated blood alcohol concentrations at several time points, along with improved self-rated alertness and lower headache severity among participants.

The significance of the Men's Fitness coverage lies in the publication's mainstream fitness audience, which extends the visibility of Quantum BioPharma's consumer-facing asset beyond the biotech investor base. For a company whose primary identity is drug development, consumer brand validation can support multiple revenue pathways, including royalties and equity interests. The trial's placebo-controlled design also matters because most recovery drinks on the market have not been tested against a placebo in a registered human trial, according to the release. That distinction could influence how regulators, retailers and consumers evaluate claims in the category.

For operators in the alcohol recovery space, the stakes reach beyond the morning after. A product with clinical data behind it may face a smoother path to shelf space and marketing claims, while competitors relying on anecdotal evidence could face tougher scrutiny. Quantum BioPharma's dual interest in the consumer brand and its broader pipeline of therapies for alcohol misuse disorders suggests the company is positioning unbuzzd as both a commercial product and a proof point for its scientific approach.

Investors can find additional details through the company's Quantum BioPharma (NASDAQ: QNTM) profile and the full Read More coverage. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. As with any forward-looking statement, actual results may differ materially from expectations, and readers should review the company's SEC filings for a full discussion of risks.

Blockchain Registration

QR Code for Blockchain Registration